Equities

CogState Ltd

CGS:ASX

CogState Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)1.08
  • Today's Change-0.02 / -1.82%
  • Shares traded41.50k
  • 1 Year change-30.99%
  • Beta0.7093
Data delayed at least 20 minutes, as of Jul 03 2024 07:10 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cogstate Limited is a neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Its principal activities are the creation, validation, and commercialization of digital brain health assessments; and design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its segments include Clinical Trials, Healthcare, and Administration. In the Clinical Trials segment, the technology and associated services are used to quantify the effect of disease and of drugs, devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical, and biotechnology companies. In the Healthcare segment, the technology and associated services are being developed as a tool for primary care physicians and/or hospitals to assess cognitive decline.

  • Revenue in AUD (TTM)62.35m
  • Net income in AUD8.28m
  • Incorporated1999
  • Employees61.00
  • Location
    CogState LtdLevel 2, 161 Collins StreetMELBOURNE 3000AustraliaAUS
  • Phone+61 39664-1300
  • Fax+61 39664-1301
  • Websitehttps://cogstate.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
IDT Australia Limited10.36m-6.55m47.25m156.00--1.72--4.56-0.0215-0.02150.03410.06390.37412.393.51---23.64-9.87-26.41-11.5776.3884.42-63.19-24.942.81--0.0907---42.03-11.97-632.59---26.04--
Cynata Therapeutics Ltd436.25k-13.65m48.50m0.00--3.95--111.18-0.0873-0.08730.00270.06830.0257--4.26---80.33-38.07-87.15-41.10-----3,127.93-513.73----0.00---94.9619.81-162.20------
Anteotech Ltd526.75k-11.46m51.83m40.00--9.71--98.40-0.0056-0.00560.00030.00220.0552--2.62---120.11-68.55-145.22-75.44-----2,176.15-1,432.10----0.1729---46.6511.41-18.08--25.84--
LTR Pharma Ltd-100.00bn-100.00bn57.03m----17.98----------0.0451----------------------------0.00---100.00---41.65------
Inoviq Ltd751.54k-6.51m58.04m85.00--3.02--77.22-0.0708-0.07080.00820.1820.03392.100.873---29.33-47.68-32.18-50.7695.07---866.27-2,527.824.93--0.0332--119.59153.3150.71------
Percheron Therapeutics Ltd624.51k-10.85m72.12m8.00--4.38--115.49-0.0157-0.01570.00090.01820.0328--0.3224---56.94-72.09-66.58-81.73-----1,737.37-6,558.90----0.001--1,026.1672.03-95.81------
Neurotech International Ltd1.28m-4.98m75.29m----13.76--58.94-0.0058-0.00580.00150.00540.1826-0.11495.67---71.23-197.33-74.66-255.24100.0779.57-390.03-1,043.8818.35--0.00--106.2283.24-131.75------
Paradigm Biopharmaceuticals Ltd8.67m-69.00m97.94m----2.91--11.30-0.2296-0.22960.02880.09620.1298--2.25---103.34-40.96-127.58-44.1399.87---796.30-466.85---348.760.0085--7.5825.42-32.26------
Argenica Therapeutics Ltd92.21k-4.67m101.43m----12.33--1,100.04-0.0511-0.05110.0010.06650.0109--0.6384---55.31---69.00-------5,067.62-----6,663.200.00--2,340.00---17.71------
Proteomics International LaboratoriesLtd1.44m-5.90m115.19m----20.12--79.72-0.0518-0.05180.01290.04370.1817--11.13---75.75-57.79-87.11-67.57-----416.78-229.69---283.470.0088---14.644.12-24.20--89.02--
Actinogen Medical Ltd337.51k-14.87m160.98m----11.72--476.97-0.0073-0.00730.00020.00510.0211--0.7341---92.99-45.55-105.88-48.24-----4,405.86-5,369.76---294.930.0037--792.7431.88-13.21--166.95--
Arovella Therapeutics Ltd139.02k-10.23m162.84m14.00--45.00--1,171.32-0.0127-0.01270.00020.00340.0249--15.15---182.82-77.12-276.07-93.2683.5663.41-7,357.19-1,471.57----0.00--45.470.3491-18.11---68.72--
Cogstate Ltd62.35m8.28m187.86m61.0024.823.3115.133.010.04430.04430.33780.33260.7757--5.58--10.306.0113.849.2254.6951.5013.287.26----0.01350.00-8.627.25-52.56---5.06--
Data as of Jul 03 2024. Currency figures normalised to CogState Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

15.12%Per cent of shares held by top holders
HolderShares% Held
Australian Ethical Investments Ltd. (Investment Management)as of 25 Jun 202416.44m9.63%
FIL Investment Management (Hong Kong) Ltd.as of 30 Apr 20244.95m2.90%
Fidelity Management & Research (Hong Kong) Ltd.as of 30 Apr 20241.95m1.14%
Mutual Trust Pty Ltd.as of 30 Jun 20231.22m0.72%
DFA Australia Ltd.as of 31 May 2024726.22k0.43%
Dimensional Fund Advisors LPas of 06 Jun 2024466.43k0.27%
Mandarine Gestion SAas of 29 Feb 202445.00k0.03%
Dimensional Fund Advisors Ltd.as of 06 Jun 202413.68k0.01%
Colonial First State Investments Ltd.as of 31 Dec 20237.42k0.00%
Seven Canyons Advisors LLCas of 31 Mar 20240.000.00%
More ▼
Data from 31 Dec 2023 - 25 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.